AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
Log in

NASDAQ:RUBYRubius Therapeutics Stock Price, Forecast & News

$6.60
+0.13 (+2.01 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.39
Now: $6.60
$6.74
50-Day Range
$4.32
MA: $5.68
$6.85
52-Week Range
$3.35
Now: $6.60
$17.17
Volume160,464 shs
Average Volume412,153 shs
Market Capitalization$531.14 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Rubius Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.20 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.92 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Employees142
Market Cap$531.14 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

How has Rubius Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have increased by 0.8% and is now trading at $6.60. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Rubius Therapeutics.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Rubius Therapeutics.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics Inc (NASDAQ:RUBY) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.04. View Rubius Therapeutics' earnings history.

What price target have analysts set for RUBY?

6 brokerages have issued twelve-month target prices for Rubius Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View analysts' price targets for Rubius Therapeutics.

Has Rubius Therapeutics been receiving favorable news coverage?

Headlines about RUBY stock have been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rubius Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutRubius Therapeutics.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 57)
  • Dr. Christopher L. Carpenter M.D., Ph.D., Chief Medical Officer (Age 63)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 56)
  • Mr. Andrew M. Oh, Chief Financial Officer (Age 47)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 50)

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.30%), BlackRock Inc. (3.76%), Capital World Investors (2.19%), JPMorgan Chase & Co. (1.46%), State Street Corp (0.82%) and Federated Hermes Inc. (0.75%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Francis M Cuss, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen. View institutional ownership trends for Rubius Therapeutics.

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Invesco Ltd., BlackRock Inc., Morgan Stanley, UBS Group AG, Deutsche Bank AG, State of Michigan Retirement System, and Bank of New York Mellon Corp. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, and Robert Langer. View insider buying and selling activity for Rubius Therapeutics.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Federated Hermes Inc., Russell Investments Group Ltd., Two Sigma Investments LP, Tekla Capital Management LLC, Geode Capital Management LLC, State of Michigan Retirement System, and Two Sigma Advisers LP. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, Francis M Cuss, and Pablo J Cagnoni. View insider buying and selling activity for Rubius Therapeutics.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $6.60.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $531.14 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.